NEW YORK (GenomeWeb News) – Hologic said after the close of the market on Thursday that Jack Cumming is replacing Rob Cascella as president and CEO of the firm, effective immediately.

The company also pre-announced third-quarter revenues of $626 million and non-GAAP adjusted EPS of $.38.

In its announcement, Hologic said that Cascella is leaving the firm for "personal reasons" but will serve as an advisor to the company through November.

For Cumming, it will be his second go-round as CEO of the company. He previously headed Hologic between 2001 and 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.